Ibogaine, explained

What ibogaine and iboga are

Iboga (Tabernanthe iboga) is a shrub native to Central Africa. Its root bark contains ibogaine, the principal alkaloid, together with eleven related alkaloids. In Gabon the plant is central to Bwiti, a spiritual tradition kept by communities from around fifty ethnic groups, who take it in rites of passage and traditional healing practices. Its use has spread to Fang communities in Equatorial Guinea and southern Cameroon.

Ibogaine was first isolated in 1901, and small doses of bark extract, with roughly 8 mg of ibogaine each, were later used legally as a stimulant. Clinical studies use far larger amounts, usually purified ibogaine hydrochloride dosed by body weight. The enzyme CYP2D6 turns ibogaine into noribogaine, which is also active and is cleared much more slowly.

Why people seek it out

In 1962 Howard Lotsof, a young New Yorker dependent on heroin, took ibogaine with friends who also used heroin. Most of them stopped the next day and described neither withdrawal nor craving. Most studies since then concern opioid withdrawal, and some have included people dependent on cocaine.

A 2026 scoping review found no randomised controlled trials of ibogaine for addiction, only uncontrolled studies and case reports. In an observational study of 30 people with opioid dependence, withdrawal eased sharply within three days, and opioid use fell most at one month, with part of the gain lasting to 12 months. A New Zealand study followed 14 people for a year: the eight who completed follow-up reported less drug use, and one participant died during treatment.

In 2024 a Stanford team reported an observational study of 30 male US special operations veterans with mostly mild traumatic brain injury, who had arranged their own treatment at a clinic in Mexico. The protocol paired oral ibogaine with intravenous magnesium, meant to protect the heart. A month later, average scores on the World Health Organization disability scale had fallen from 30.2 to 5.1, and scores for PTSD, depression and anxiety had fallen by at least 81% on average, with no serious or unexpected side effects. There was no control group, the men also received other therapies at the clinic, and the authors call for controlled trials.

What a treatment involves

Preparation starts weeks before travel, with the screening described below. People on methadone or buprenorphine first move, under medical supervision, to a short-acting opioid such as oral morphine, because ibogaine can strengthen opioids still in the body. Depending on the dose, the switch takes from about one week to several; in a Dutch hospital study, patients spent eight days on morphine first.

The Global Ibogaine Therapy Alliance (GITA), a non-profit, published clinical guidelines in 2015 and revised them in 2016. They advise repeating the ECG on arrival and testing urine for drugs and pregnancy. Many protocols start with a test dose of 2 to 3 mg per kg and give the rest within a few hours. The veterans’ clinic kept the total below 14 mg per kg, the Dutch hospital gave a single dose of 10 mg per kg, and GITA treats more than 12 mg per kg as a higher cardiac risk.

Within a few hours of the dose comes a dreamlike phase of roughly four to eight hours, usually with closed eyes and often revisiting memories, then a reflective phase that runs to about 20 hours, and residual effects over the next two or three days. In the Dutch study every patient temporarily lost coordination and could not walk without support, and in the veterans’ study 40% needed treatment for headache and 23% for nausea. GITA advises a dark, quiet room.

The heart risk

Ibogaine and noribogaine block hERG potassium channels in heart muscle, delaying the heart’s electrical recovery after each beat. An ECG shows this as a longer QT interval, which can trigger torsades de pointes, a fast rhythm of the lower chambers that can end in cardiac arrest. It also tends to slow the pulse and lower blood pressure, which adds to the risk.

A forensic review published in 2012 examined 19 deaths outside West Central Africa between 1990 and 2008, occurring 1.5 to 76 hours after a dose. In 12 of the 14 cases with adequate post-mortem data, heart disease, other drugs or both explained or contributed to the death, and seizures during alcohol or benzodiazepine withdrawal were a further risk factor. Later case reports describe dangerous rhythms, some fatal, in people aged 19 to 64 with no history of heart disease, all after ibogaine taken without medical monitoring.

Screening lowers the risk but does not remove it. Of 14 patients without known heart disease in the Dutch study, half reached a corrected QT interval (QTc) above 500 ms, six stayed above 450 ms beyond 24 hours and seven developed a slow heart rate; no torsades occurred and the changes reversed. The veterans’ study, which gave everyone magnesium, saw no clinically meaningful QT prolongation, but it relied on visual checks of a continuous monitor rather than formal ECG measurements, so how much the magnesium helped remains unclear.

Because noribogaine clears slowly, the danger can outlast the first day. People whose CYP2D6 enzyme works slowly, through their genes or other medicines, are exposed to more of the drug for longer, and low potassium or magnesium has featured in fatal cases. Some people also develop insomnia, irritability, delusions or hallucinations in the days after treatment.

Screening and monitoring

Careful screening starts with a resting 12-lead ECG. GITA excludes anyone with a QTc above 450 ms for men or 470 ms for women, and asks a cardiologist to weigh borderline readings, past arrhythmias or heart attacks, murmurs and a family history of sudden cardiac death before 50. Blood tests should cover potassium, magnesium, and kidney and liver function. Electrolytes outside the normal range must be corrected first, and liver enzymes above 2.5 times normal rule a person out, because a damaged liver can make the effects much stronger or longer.

The clinic in the veterans’ study told patients to stop all psychiatric medicines, benzodiazepines, stimulants, beta blockers, calcium channel blockers, diuretics, corticosteroids, serotonergic drugs and anything that inhibits CYP2D6. Antidepressants that raise serotonin add a risk of serotonin syndrome, and several also slow CYP2D6. Any change should be a gradual taper planned with the prescribing doctor and followed by a fresh psychiatric assessment, not a sudden stop days before travel. A 2026 review also recommends testing CYP2D6 genes beforehand.

During and after the dose the heart should be watched continuously by staff trained in advanced cardiac life support, with a defibrillator, oxygen, magnesium, potassium and emergency drugs at hand. The Dutch team took an ECG every half hour for 12 hours, gave magnesium whenever the QTc passed 500 ms, and had a cardiologist decide after 24 hours whether monitoring could stop.

The law

Legal status was checked on 1 October 2026 and can change. In the United States, ibogaine is in Schedule I of the Controlled Substances Act of 1970, the strictest category, for drugs with a high potential for abuse and no currently accepted medical use.

In Europe, France classified the iboga plants and ibogaine as narcotics by an order of 12 March 2007. Italy added ibogaine and the iboga plant to Table I of its narcotics law by a decree of 1 August 2016. Denmark lists ibogaine as a controlled substance that may be used only for medical and scientific purposes. No medicine containing ibogaine is authorised anywhere in the European Union.

New Zealand has listed ibogaine as a prescription-only medicine since 2010, although it remains unapproved there. Canada added it to its Prescription Drug List in 2017; according to ICEERS, it cannot be obtained legally there until clinical trials have been completed. In Mexico, where the veterans were treated, the researchers noted that ibogaine use is not restricted. Where nothing is regulated, every safeguard described above depends on the clinic alone.

Choosing a provider

• Ask who the doctor in charge is and whether a clinician trained in advanced cardiac life support stays on site until the heart has settled.
• Expect to send an ECG, blood tests and a full medicine list before booking. Avoid a clinic that asks for none of this.
• Ask how the heart is monitored, for how long, and what staff do if the QTc rises.
• Check for a defibrillator and emergency drugs on site, a written emergency plan and a 24-hour hospital nearby; GITA suggests no more than 30 minutes away.
• Expect written information on the risks, the legal position and the experimental status of the treatment, and a consent form to sign.
• Plan any medicine change, including a switch from methadone or buprenorphine, with your own doctor as well as the clinic.
• Ask about aftercare: discharge no earlier than 72 hours after the dose and contact for at least six weeks.

A 2013 death in New Zealand shows why these checks matter. A 45-year-old woman with a history of opioid use was found dead at the clinic the morning after her last dose. The post-mortem found no significant heart disease and called an ibogaine-related arrhythmia a strong possibility. The Health and Disability Commissioner found that monitoring had fallen short of the clinic’s own protocol, that the doctor had left for overseas while she was still in treatment, and that she had never signed a consent form.